View More Recent Stories
-
GRAIL, Inc. (GRAL): Results of Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
-
GRAIL, Inc. (GRAL) Reports Q2 Loss of $51.06/sh
-
GRAIL (GRAL) to Commence Separate Trading on Nasdaq
